Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 2/20 | 0.39 |
| ▸ | POLQ | O75417 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | TACR2 | P21452 | 2/20 | 0.37 |
| ▸ | TACR1 | P25103 | 2/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15717896 | 0.91 | GPBAR1 (0.48) | MLYCDGPBAR1TACR2TACR1MCHR1 | |
| SCHEMBL15717246 | 0.90 | MCHR1 (0.40) | MLYCDGPBAR1TACR2TACR1NTRK1 | |
| SCHEMBL15717894 | 0.89 | CYP11B2 (0.41) | MLYCDGPBAR1 | |
| SCHEMBL15717240 | 0.89 | SCN5A (0.40) | MLYCDGPBAR1HDAC4TACR2TACR1 | |
| SCHEMBL15718260 | 0.87 | RPS6KA3 (0.40) | TACR1 | |
| SCHEMBL15717624 | 0.87 | RET (0.43) | — | |
| SCHEMBL17309067 | 0.86 | MLNR (0.41) | — | |
| SCHEMBL15718256 | 0.85 | GRM2 (0.37) | MLYCDGPBAR1TACR2TACR1NTRK1 | |
| SCHEMBL15718299 | 0.84 | GRIN1 (0.40) | GPBAR1TACR2TACR1NTRK1 | |
| SCHEMBL15739614 | 0.82 | MLYCD (0.43) | MLYCDPOLQGPBAR1HDAC4NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190030009-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | NOVARTIS AG (CH) | 2019-01-31 | — | — | US | claimed |
| EP-3405468-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | Novartis AG (CH) | 2018-11-28 | — | — | EP | claimed |
| EP-2925757-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2017-10-04 | — | — | EP | claimed |
| WO-2017125898-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | NOVARTIS AG (CH) | 2017-07-27 | — | — | WO | claimed |
| US-9556169-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2017-01-31 | — | — | US | claimed |
| US-20160333012-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2016-11-17 | — | — | US | claimed |
| US-20150344471-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | claimed |
| EP-2925757-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | Novartis AG (CH) | 2015-10-07 | — | — | EP | claimed |
| US-20150011522-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2015-01-08 | — | — | US | claimed |
| US-8871754-B2 | Compounds and compositions for the treatment of parasitic diseases | IRM LLC (BM) | 2014-10-28 | — | — | US | claimed |
| US-20140155367-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | claimed |
| WO-2014078802-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-05-22 | — | — | WO | claimed |
| US-20190030009-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | NOVARTIS AG (CH) | 2019-01-31 | — | — | US | disclosed |
| US-9926314-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2018-03-27 | — | — | US | disclosed |
| US-9926314-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2018-03-27 | — | — | US | disclosed |
| US-9926314-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2018-03-27 | — | — | US | disclosed |
| US-20140155367-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | disclosed |
| US-20140155367-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | disclosed |
| WO-2014078802-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078802-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344471-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | MLYCD 2108/4885POLQ 4176/4885GPBAR1 43/4885 |
| US-20150011522-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | MLYCD 2108/4885POLQ 4176/4885GPBAR1 43/4885 |
| US-20140155367-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | MLYCD 2108/4885POLQ 4176/4885GPBAR1 43/4885 |
| US-20160333012-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | MLYCD 2108/4885POLQ 4176/4885GPBAR1 43/4885 |
| US-20190030009-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | PI4KA, PI4K2A, PIP4K2A | MLYCD 3623/4885POLQ 3026/4885GPBAR1 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.